#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pulmonary fibrosis Chronic granulomatous disease Systemic lupus erythematosus Transitional cell cancer of the renal pelvis and ureter Haemophilia Adenocarcinoma pancreas Autoimmune demyelinating disease Deafness Hyperoxaluria Bronchopulmonary aspergillosis Lung adenocarcinoma Barth syndrome Kearns-Sayre syndrome Dedifferentiated liposarcoma Endometrial adenocarcinoma More trials…

    Learn about Rare Diseases

    Paroxysmal nocturnal haemoglobinuria – Diagnostics Kearns-Sayre syndrome Bronchopulmonary dysplasia Glycogen storage disease type II – Trials in Disease Piriformis syndrome – Trials in Disease Haemophilia B with anti factor IX – Life with Disease Cystic fibrosis Vascular malformation – Diagnostics Indolent systemic mastocytosis – Treatment Ocular melanoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VMX-C001 Bleomycin Lutetium (177Lu) Edotreotide Pralsetinib Bay 3018250 Gimeracil Lenalidomide Elenestinib Phosphate Ro7790121 Tepotinib Flucloxacillin Ustekinumab CAL101 Delafloxacin Oxybuprocaine Palonosetron Propranolol Hydrochloride Azd8421 Arginine Vericiguat More therapies…

    Learn about Your Condition

    Stomatitis Arrhythmia Actinic cheilitis Dermatomyositis Graft versus host disease Myositis Macular degeneration Sinus rhythm Oesophageal carcinoma B-cell type acute leukaemia Keratosis follicular Asthmatic crisis Metastases to rectum Pyrexia Postoperative wound infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Central nervous system neoplasm

  • Study to Find the Right Dose and Safety of Lutetium (177Lu) Edotreotide and Arginine-Lysine in Children with Somatostatin Receptor-Positive Tumors

    Recruiting

    1 1 1
    Investigated Diseases:
    • Central nervous system neoplasm
    • Neuroendocrine tumour
    • Peripheral primitive neuroectodermal tumour of soft tissue
    Investigated Drugs:
    • Lutetium (177Lu) Edotreotide
    • L-Arginine Hydrochloride
    • L-Lysine Hydrochloride
    France Italy Spain

  • Study of Gadobutrol for MRI in Adults with Cerebrospinal Fluid Disorders, Including Hydrocephalus and Brain Tumors

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Central nervous system neoplasm
    • Cognitive disorder
    • Hydrocephalus
    Investigated Drugs:
    • Gadobutrol
    Norway

  • Study on APL-101 for Treating Advanced Solid Tumors and Non-Small Cell Lung Cancer with MET Changes in Patients

    Recruiting

    1 1 1
    Investigated Diseases:
    • Central nervous system neoplasm
    • Neoplasm
    • Non-small cell lung cancer
    Investigated Drugs:
    • Apl-101
    France Hungary Italy Spain

  • Safety of autologous NK cells with IL‑15 and CD45RA‑negative T cells with NKG2D CAR in children, adolescents and young adults with high‑grade brain tumors

    Not yet recruiting

    1 1 1
    Investigated Diseases:
    • Central nervous system neoplasm
    Spain

  • Study on the Effects of Selpercatinib in Children with Advanced RET-Altered Solid Tumors or Primary Central Nervous System Tumors

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Selpercatinib
    Denmark France Germany Italy Spain

  • Study on Larotrectinib for Treating Children with Advanced Solid Tumors with NTRK Fusion

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Central nervous system neoplasm
    • NTRK gene fusion overexpression
    • Neoplasm malignant
    Investigated Drugs:
    • Larotrectinib Sulfate
    Czechia Denmark France Germany Ireland Italy +3

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!